To explore the mechanism of estrogen-induced growth of normal endometrium, the transactivation system of the cyclin D1 gene was analysed using cultured normal endometrial glandular cells. Estradiol (E2) treatment of cultured normal endometrial glandular cells induced upregulation of c-Jun, and then cyclin D1 proteins, followed by serial expressions of cyclins E, A and B1 proteins. Increase in the mRNA expression of cyclin D1 preceded the protein expression of cyclin D1 under E2 treatment. A luciferase assay using deletion constructs of the cyclin D1 promoter indicated that E2-induced increase in transcriptional activity was observed in reporters containing AP-1-binding site sequence, and that in the absence of E2, cotransfection of c-Jun also showed increase of transcriptional activity in the same reporters with AP-1 sequence. A gel shift assay using nuclear extract from E2-treated endometrial glandular cells and AP-1 sequences of the cyclin D1 promoter indicated specific binding between c-Jun protein and the promoter. Transfection of c-jun antisense oligonucleotides to the glandular cells resulted in the suppression of the E2-induced upregulation of cyclin D1 mRNA and protein. These findings suggest that E2-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of cJun to the AP-1 sequences.
Introduction
Proliferation of normal endometrial glandular cells and endometrial carcinoma cells expressing estrogen receptors (ER) is known to be increased by estrogen (Strauss and Coutifaris, 1999) . To understand the estrogeninduced growth mechanism of the normal and malignant endometrium is of particular importance for the prevention of endometrial neoplasia in women under unopposed estrogen environment, and also for the development of better hormonal treatment of endometrial carcinoma, the most common malignancy in the female genital tract (Lurain, 2002) . It is also true for appropriate stimulation of endometrial growth in women with infertility, since the number of infertile couples especially due to implantation failure is increasing in recent years (Speroff et al., 1999) . Although the mechanisms for estrogen-dependent growth of these cells have previously been investigated from various aspects, including of upregulation of steroid receptors (Gronroos et al., 1987; Lessey et al., 1988) , altered function of steroid metabolizing enzymes (Tseng and Mazzella, 1980) , autocrine or paracrine effect of growth factors and cytokines (Giudice, 1994) , very little is known about the direct effect of estrogen on the machineries propelling the cell cycle.
Cell cycle regulators such as cyclins, cyclin-dependent-kinases (cdks) and cdk inhibitors are essential in cell cycle control, that is, the cyclins form a complex with the respective cdks, and the kinase activities generated by these complexes phosphorylate the retinoblastoma gene products (pRb), resulting in cell cycle progression (Nurse, 1994; Sherr, 1994) . We previously reported the expression of these cell cycle regulators in normal cycling endometria, and the overexpression of various classes of cyclins and cdks in endometrial carcinomas Nikaido et al., 1996; Shiozawa et al., 1996 Shiozawa et al., , 1997 . In addition, we demonstrated that progestins upregulate the expression of a cdk2 inhibitor, p27Kip1 (p27), via post-translational mechanism, and that p27 plays a crucial role in the progestin-induced growth suppression of normal and malignant endometrial glandular cells (Shiozawa et al., 2001a) . On the other hand, the intracellular molecules mediating between estrogen and cell cycle regulators in endometrial tissues remain undetermined. The possible mechanisms for estrogen-induced activation of cyclins have been proposed from the studies using breast cancer cell lines (Altucci et al., 1996; Lee et al., 1998; Sabbah et al., 1999; Castro-Rivera et al., 2001; Liu et al., 2002a) ; the transcription factors involved have been characterized, although the results in breast cancer cells are controversial probably due to the differences of cell context. Therefore, the present study was conducted to identify the molecules directly involved in estrogeninduced progression of the cell cycle in normal and neoplastic endometrial glandular cells.
Results

Serial upregulation of cyclins and cdks under treatment with estrogen in normal endometrial glandular cells
To analyse the involvement of cell cycle regulators in the growth of normal endometrial glands, we first examined the immunohistochemical expression of cyclin and cdks in human endometrial tissues. The expression of cyclin D1, E, A and B1 was sporadically observed in the nuclei of glandular cells in the proliferative phase ( Figure 1a ). Cyclin D1-and cyclin E-positive cells were often positive for cdk4 and cdk2, respectively ( Figure 1b ). Cyclin A-and cyclin B1-positive cells were also positive for cdc2. In addition, these cyclin/cdk-positive cells expressed Ki-67, suggesting that cyclins and cdks are functionally involved in the growth regulation of endometrial glandular cells.
We then examined the expression of cyclins and cdks in primarily cultured endometrial glandular cells from normal proliferative endometrium. These cells were positive for ER-a and cytokeratin (data not shown). Uptake of [ 3 H]thymidine was increased by treatment with 17b-estradiol (E2) in a dose-dependent manner (Figure 2) . The difference in the uptake between the control and E2 (10 À6 M)-treated group reached a significant difference with a relative ratio 1.4570.20 (P ¼ 0.01) after 72 h of incubation. On the other hand, E2-induced [ 3 H]thymidine uptake was suppressed by treatment with progesterone (P4) at 10 À8 M after 48 and 72 h. Cell cycle analysis using flow cytometry showed that the S-phase fraction of E2-untreared cells was 13.2%, and those of E2-treated cells for 12 and 24 h were 18.2 and 20.0%, respectively. These findings indicate that our in vitro model using the cultured endometrial glandular cells is suitable for investigation of estrogen-induced cell proliferation.
Expression of cell cycle regulators under E2 treatment was analysed using these cultured glandular cells. Western blot analysis demonstrated that expression of cyclin D1 was first observed 4 h after the E2 (10 À6 M) treatment, followed by serial expressions of cyclin E, cyclin A and cyclin B1 (Figure 3a) . pRb phosphorylation was observed after 24 h (Figure 3a , upper arrow). The expression of cdk4, cdk2 and cdc2 was also increased by E2 treatment. Analyses using semiquantitative reverse transcriptase-polymerase chain reaction Estrogen-induced cyclin D1 expression in human endometrium T Shiozawa et al (RT-PCR) revealed that the mRNA expression of cyclin D1 appeared by 2 h, and then increased with a peak at 12 h after E2 treatment (Figure 3b ). Regarding the expression of cyclin E mRNA, it appeared by 4 h and increased until 24 h after E2 treatment (Figure 3b ). The expression of both cyclin D1 and cyclin E mRNAs preceded that of cyclin D1 and cyclin E proteins, respectively. Immunoprecipitation experiments using cell lysates from E2-stimulated cultured glandular cells confirmed the complex formation of cyclin D1 with cdk4, and that of cyclin E with cdk2 ( Figure 3c ). To further examine the function of these complexes, we performed a histone H1 kinase assay. Kinase activity was observed when cdk4 and cdk2 were immunoprecipitated in E2-treated cells, but not in E2-untreated cells (Figure 3c ). These findings indicate that E2 treatment serially upregulates cyclins and cdks, and that these events constitute the initial step in E2-induced growth of normal endometrial glandular cells.
Estrogen-induced activation of cyclin D1 via binding of c-Jun with the AP-1 sequence of the promoter
We then investigated the molecular aspects of estrogeninduced upregulation of cyclin D1. Screening of the cyclin D1 promoter revealed that it lacks an estrogenresponse element (ERE), but contains an AP-1-binding site sequence located at À953 to À947 (Motokura and Arnold, 1993). Promoters of Jun and Fos are known to have functional EREs (Weisz and Rosales, 1990; Hyder et al., 1995) , and expressions of c-Jun and c-Fos have reportedly been induced by estrogen in animal models (Webb et al., 1993) . Our immunohistochemical analysis in human endometrial tissues revealed that expressions of c-Jun in the glandular cells was observed only in the proliferative phase (Figures 1c and d ), but c-Fos expression was observed in both the proliferative and secretory phases. Western blot analysis using cultured glandular cells showed an induction of c-Jun expression 2 h after E2 treatment, which preceded the expression of cyclin D1 (Figure 3a ). Slight expression of c-Fos was also observed after E2 treatment. Hence, we hypothesized that either c-Jun, c-Fos, or both are involved in the upregulation of cyclin D1 in E2-induced growth of endometrial glandular cells.
To address this hypothesis, we analysed the cyclin D1 transcription in cultured endometrial glandular cells by a luciferase assay using plasmids containing various sizes of deletion constructs ranging from À1793 to À43 of the cyclin D1 promoter (Figure 4a ). The results indicated that, without E2 treatment, the transcriptional activity was low in most of the promoter constructs. In contrast, under E2 treatment, there were two reporters showing elevated activities with significant differences, being consistent with the E2-induced upregulation of cyclin D1 mRNA. And, both of these two reporters contained the AP-1 sequence, suggesting that E2-induced expression of cyclin D1 is mediated by the AP-1 sequence of the promoter. To further analyse whether c-Jun or c-Fos or both were functionally involved in the transcriptional activation of cyclin D1, we performed a luciferase assay in cultured glandular In Western blot analyses (a), expression of cyclin D1 was first observed 4 h after E2 treatment, followed by serial expressions of cyclin E, cyclin A and cyclin B1. The expression of cdk4 and cdk2 also showed an increase after E2 treatment. pRb phosphorylation was observed 24 h after E2 treatment (upper arrow). Upregulation of c-Jun and slight increase in c-Fos expression were observed 2 h after E2 stimulation. In semiquantitative RT-PCR for cyclin D1 and cyclin E (b), mRNA expression of cyclin D1 appeared by 2 h, and then increased with a peak at 12 h after E2 treatment. Cyclin E mRNA appeared by 4 h and increased until 24 h after E2 treatment. In immunoprecipitation and histone H1 kinase assays (c), complex formation of cyclin D1-cdk4 and cyclin E-cdk2 was observed, and these complexes showed histone H1 kinase activities in E2-treated endometrial glandular cells Estrogen-induced cyclin D1 expression in human endometrium T Shiozawa et al cells, using the same set of plasmids containing various sizes of cyclin D1 promoter deletion constructs, along with cotransfection of either a c-Jun-or a c-Fosexpression plasmid in the absence of E2. Transcriptional activity in the two reporters containing the AP-1 sequence was increased when c-Jun was cotransfected with significant differences, but not when c-Fos was cotransfected (Figure 4b) .
To evaluate the specificity of binding of the AP-1 sequence with the AP-1 protein from the endometrial glandular cells, we performed a gel shift assay and a competition assay. In this study, three different DNA probes were used, that is, PRAD-D1, promoter DNA containing an AP-1 sequence in the cyclin D1 promoter (TGAGTCA): PRAD-M, a mutant of the AP-1 sequence and PRAD-C; a consensus AP-1-binding sequence (TGACTCA). The gel shift assay indicated that a specific band shift was observed when E2-treated nuclear extract was applied with PRAD-D1 and PRAD-C (Figure 5a ; lanes 4 and 6). In contrast, the bands were very weak when a nuclear extract from E2-untreated cells was applied with PRAD-D1 and PRAD-C (Figure 5a ; lanes 1 and 3). Specific bands were not detected when PRAD-M was applied (Figure 5a ; lanes 2 and 5). The competition assay showed that an excessive amount of cold PRAD-D1 completely eradicated the specific band (Figure 5a ; lane 10). Addition of cold PRAD-C also eradicated most of the above specific bands (Figure 5a ; lane 12). In contrast, addition of cold PRAD-M did not affect the bands (Figure 5a ; lane 11).
All of these findings indicate that the protein extracted from E2-treated endometrial glandular cells binds specifically to the AP-1 sequence of the cyclin D1 promoter. In the gel shift assay, band supershift was not observed when anti-c-Jun or anti-c-Fos antibodies used for immunostaining were added (Figure 5a ; lanes 8 and 9). However, when anti-AP-1 antibodies designed for the binding inhibition assay were applied, band supershift was observed with the anti-c-Jun antibody ( Figure 5b ; lane 2). These findings indicate that c-Jun protein specifically binds to the AP-1 sequence of the promoter. It is likely therefore that E2-induced activation of cyclin D1 expression is mediated by binding of c-Jun with the AP-1 sequence of the cyclin D1 promoter in normal endometrial glandular cells.
Finally, to confirm the functional involvement of cjun in E2-induced upregulation of cyclin D1 in normal endometrial glandular cells, we performed c-jun silencing experiments using antisense oligonucleotides. E2 treatment induced upregulation of both c-jun and cyclin D1 mRNAs and the respective proteins ( Figure 6 In luciferase assays, reporter plasmids containing various sizes of deletion constructs were transfected into normal endometrial glandular cells, with or without E2 treatment (a), and elevated activities were observed in the two reporters (nos. 1 and 2) containing the AP-1 sequence under E2 treatment. In luciferase assays using the same reporters with cotransfection of c-Jun or c-Fos in the absence of E2 (b), elevated activities were observed in the same two reporters containing AP-1 site (nos. 1 and 2), only when cotransfected with c-Jun but not with c-Fos. The structure of the cyclin D1 promoter deletion constructs fused to the luciferase reporter gene is indicated below the graphs. *P ¼ 0.028 when compared to the activity using the same reporter without E2. **P ¼ 0.031 when compared to the activity using the same reporter without E2. #Po0.01 when compared to the activity using the same reporter with control vector or with c-Fos. ##Po0.001 when compared to the activity using the same reporter with control vector or with c-Fos
Estrogen-induced activation of cyclin D1 in endometrial carcinoma Ishikawa cells without involvement of the AP-1 sequence
We also examined the effect of E2 treatment on the expression of cyclins in endometrial carcinoma Ishikawa cells. Western blot analysis showed that expression of cyclin D1 was noted even before E2 treatment, and a slight increase of cyclin D1 expression was observed after E2 treatment. A luciferase assay using the same set of plasmids containing various sizes of cyclin D1 promotor deletion constructs revealed that E2-induced increase in the activity was most prominent in the reporter containing the E2F-binding site, but was not observed in the reporters having the AP-1 sequence (data not shown). These findings suggest that the mechanism of E2-induced activation of cyclin D1 in endometrial carcinoma Ishikawa cells is different from that of normal endometrial glandular cells.
Discussion
In this study, to explore the molecular mechanism of estrogen-induced cell proliferation, we analysed the transcriptional activation system of the cyclin D1 gene. Among various cyclins, cyclin D1 is the only molecule whose expression is controlled by extracellular signals (Sherr, 1994) . In our primarily cultured glandular cells from normal human endometrium, expression of cyclin D1 protein appeared 4 h after E2 treatment, followed by serial expressions of cyclins E, A and B1. Such sequential expression of cyclins is the same as that in other cells stimulated by various mitogens, and expression of cyclin D1 protein was reportedly increased approximately 4-6 h after the stimulation. Therefore, upregulation of cyclin D1 seems to be crucial also in the estrogen-induced growth of endometrial glandular cells. The activation of the cyclin D1 gene is predominantly by transcription (Sherr, 1994) , and its promoter contains Estrogen-induced cyclin D1 expression in human endometrium T Shiozawa et al multiple regulatory elements such as TRE, E2F, Oct, Sp1 and a cAMP response element (Motokura and Arnold, 1993; Herber et al., 1994) . Previous promoter analyses suggested that the assembly of transcription factors is highly variable and dependent on multiple factors including the mitogen and cell context. Overexpression of p60v-src in MCF-7 breast cancer cells activates cyclin D1 and involves activation of a cAMPresponse element-binding protein (CREB) and an activating transcription factor-2 (ATF-2), which interacts with a CRE at À66 in the cyclin D1 promoter (Lee et al., 1998) . The enhanced expression of cyclin D1 by TGF-a is mediated by early growth response protein (Egr-1) via a cis-regulatory region spanning nucleotides À144 to À104 of the cyclin D1 promoter (Yan et al., 1997) . Expression of p21ras and p300 activated the cyclin D1 gene promoter in JEG-3 human trophoblasts through interaction of proteins at a distal AP-1 sequence at À954 in the promoter (Albanese et al., 1995; Albanese et al., 1999) . However, the promoter of cyclin D1 lacks an ERE, and the mechanism for estrogen-induced activation of cyclin D1 remains to be elucidated. The present study demonstrated that estrogen-induced activation of the cyclin D1 gene is mediated by binding of c-Jun to the AP-1 sequence of the cyclin D1 promoter. A luciferase assay using plasmids containing various sizes of deletion constructs indicated that the AP-1 sequence of the promoter is essential in E2-induced activation. After E2 treatment, expression of c-Jun preceded the cyclin D1 expression, and cotransfection of c-Jun and a gel shift mobility assay indicated the specific binding of the AP-1 sequence with c-Jun, but not with cFos. Generally, the effect of AP-1 transcription factors, such as c-Jun and c-Fos, encompasses a variety of reactions to the target gene activation (Curran and Franza, 1988) . AP-1 mediates basal level enhancer function and transcriptional activation in response to serum or phorbol ester (Ryseck et al., 1988) . c-Jun is important in promoting progression of the cell cycle, including the DNA synthesis or the S phase (Riabowol et al., 1992) . On the other hand, AP-1 is also a negative trans-acting factor for several genes including c-Fos, MyoD (Li et al., 1992) , insulin (Inagaki et al., 1992) and human chorionic gonadotropin (hCG) (Pestell et al., 1994) . Both c-jun and c-fos have functional ERE, and E2 treatment caused the expression of c-Jun or c-Fos at the mRNA and protein levels in the uteri of various animals (Webb et al., 1993) . In our study of the human endometrium in vivo, expression of c-Jun was observed in the proliferative, but not in the secretory phase of the menstrual cycle. This is consistent with a previous study for localization of c-jun mRNA in the proliferative endometria (Salmi et al., 1998) . Thus, although the transcriptional action of c-Jun is either positive or negative, possibly due to the combination of structure of c-Jun and a target gene context (Baichwal et al., 1992) , our study showed that c-Jun is important as a positive mediator for transcriptional activation of the cyclin D1 gene in estrogen-induced proliferation of endometrial glandular cells.
Mechanisms of estrogen-induced growth of the target cells have been studied exclusively in breast cancer cells.
Although the results from the previous studies are controversial, several mechanisms have been proposed. Estrogen-induced expression of c-Fos and its complex formation with pS1 was reported in MCF-7 cells (Duan et al., 1998) , and specific inhibition of AP-1 activity was reported to block the growth of these cells (Liu et al., 2002b) . Altucci et al. (1996) reported that estrogeninduced expression of cyclin D1 was mediated by a À944 to À136 region of the promoter in simvastatin-treated MCF-7 cells, and that estrogen-induced pS2 preceded the expression of cyclin D1, suggesting the possible involvement of the AP-1 site and of pS2 as a mediator for cyclin D1 expression. On the other hand, estrogeninduced expression of cyclin D1 in MCF-7 and HeLa cells has been reported to occur through a cAMPresponsive element located at À96 to À29 sites (Sabbah et al., 1999; Liu et al., 2002a) , and this response was mediated by the binding of ATF-2 homodimers or ATF-2/c-Jun heterodimers (Sabbah et al., 1999) . Furthermore, they also suggested that the AP-1 sequence of the promoter was rather inhibitory for cyclin D1 transcription in estrogen stimulation. Another report suggested the involvement of GC-rich Sp1-binding sites at À143 to À110 in E2-induced upregulation of cyclin D1 (CastroRivera et al., 2001). Our study has proposed a mechanism that E2-induced upregulation of cyclin D1 is mediated through binding of c-Jun to the AP-1 site of the promoter. We presume that upregulation of c-jun occurs transcriptionally and the following phenomena occur sequentially, that is, E2-ER complex first binds to the functional ERE located at the promoter of c-jun gene, and then c-Jun binds to the AP-1 sequence of the cyclin D1 gene. However, it should be noted that c-Jun levels rise quickly with a peak at 4 h and then drop off, and that cyclin D1 mRNA and protein levels do not peak until 12 and 24 h in the present study. Therefore, it may also be possible that there is another pathway of AP-1 activation, that is, E2-ER acts directly at the AP-1 element by serving as a coactivator for c-Jun, as suggested by Kushner et al. (2000) .
In conclusion, our study showed that estrogeninduced upregulation of cyclin D1 plays an important role in the growth of normal endometrial glandular cells, and its transcriptional activation is mediated by binding of c-Jun to the AP-1 sequence of the promoter. In endometrial carcinoma Ishikawa cells, our study suggested that the mechanism for estrogen-induced upregulation of cyclin D1 is different from that in normal endometrial cells. However, further researches are needed to clarify the mechanisms how ER and c-Jun interact at the AP-1 sites in normal endometrial glandular cells, and to elucidate the molecular pathways for cyclin D1 activation in endometrial carcinomas.
Materials and methods
Immunohistochemistry
A total of 20 normal endometrial tissue specimens obtained from 20 women (aged 35-45 years) were subjected to immunohistochemical staining with the approval of the Ethical Committee of Shinshu University, Japan, after obtaining written consent from the patients. Immunohistochemical staining was performed using an SAB-PO detector kit (Nichirei, Tokyo, Japan) as previously described . Anti-c-Jun and anti-c-Fos antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) for immunohistochemistry and from Oncogene (San Diego, CA, USA) for the gel shift assay.
Cell culture
Endometrial carcinoma cell An Ishikawa ER-a-positive endometrial carcinoma cell line was kindly provided by Dr Nishida at Tsukuba University. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% FCS (GIBCO, Grand Island, NY, USA).
Normal glandular cells The isolation and culture of glandular cells was performed as previously described (Shiozawa et al., 2001a) . Only primarily cultured cells were used in all experiments. Before the E2 stimulation experiments, normal glandular cells and Ishikawa cells were pretreated with rapamycin (GIBCO) (500 ng/ml) in a serum-starved medium for 24 h to synchronize them to the G1 phase of the cell cycle. Then, the cells were cultured for 24 h without rapamycin with the same medium to wash out the effect of the agent. H]thymidine incorporation assay was performed as previously described (Shiozawa et al., 2001a) .
Cell cycle analysis
The cell cycle was analysed in E2-treated normal endometrial glandular cells and E2-treated Ishikawa cells, using a cycleTEST (Becton Dickinson, Franklin Lakes, NJ, USA) and FACScan flow cytometry (Becton Dickinson).
Western blotting
Expressions of the cell-cycle-related molecules in cultured normal glandular cells after estrogen treatment were examined by Western blotting as described previously (Shiozawa et al., 2001b) .
RT-PCR
Estrogen-induced expression of cyclin D1 mRNA and cyclin E mRNA was evaluated by semiquantitative RT-PCR as described previously (Takano et al., 2000; Kaneuchi et al., 2003) . Glyceraldehyde-3-phosphatase dehydrogenase (GAP) was used as a control.
c-jun silencing experiment c-jun antisense oligonucleotides (5 0 -CGTTTCCATCTTTG-CAGT-3 0 ) and c-jun sense oligonucleotide (5 0 -ACTGCAAA-GATGGAAACG-3 0 ) (Miao and Ding, 2003) were transfected to cultured endometrial glandular cells using the EffecteneTM Transfection Reagent (Qiagen, Hilden, Germany), according to the manufacturer's instructions for 24 h after the rapamycin treatment. After the medium was changed, E2 of 10 À6 M was added. The expression of c-Jun mRNA and protein and was evaluated by semiquantitative RT-PCR (Miao and Ding, 2003) and Western blotting 3 h after addition of E2, and that of cyclin D1 mRNA/protein was also evaluated by semiquantitative RT-PCR (Kaneuchi et al., 2003) and Western blotting 6 h after addition of E2.
Immunoprecipitation
Complex formation between cyclin D1 and cdk4, as well as cyclin E and cdk2, in E2-treated (10 À6 M, 24 h) and E2-untreated normal endometrial glandular cells was examined by immunoprecipitation as previously described (Shiozawa et al., 2001b) . The detection of associated proteins was carried out using antibodies against cyclin D1 (Progen, Heidelberg, Germany) and cyclin E (Santa Cruz Biotechnology).
Histone H1 kinase assay
The kinase activity of the cyclin D1/cdk4 and cyclin E/cdk2 complexes in E2-treated (10 À6 M, 24 h) and E2-untreated normal endometrial glandular cells was evaluated by the detection of radio-labeled histone H1 protein as previously described (Shiozawa et al., 2001b) .
Luciferase assay
Plasmid cyclin D1 promoter-luciferase reporter constructs were a kind gift from Professor AK Rutsgi, USA (Yan et al., 1997) . The constructs contained eight different sizes of deleted cyclin D1 promoter (ranging from À1749 to þ 35, Figure 4 ), inserted to a promoterless vector, pA3LUC. c-Jun and c-Fos expression vectors were kind gifts from Professor T Curren, USA (Sonnenberg et al., 1989) .
Luciferase assay Isolated human endometrial glandular cells or Ishikawa cells (2 Â 10 5 ) were dispersed in type IV collagencoated 24-well plates and incubated for 24 h with Ham's F12 þ 15%FCS until DNA transfection. Then, 0.5 mg of plasmid DNAs were transfected into the above cultured normal glandular cells using the EffecteneTM Transfection Reagent with or without 10 À6 M of E2. At 72 h after transfection, the luciferase assays were performed as indicated by the manufacturer's protocol (Dual reporter system, Promega, Madison, WI, USA). Activities were normalized using the pRL-SV40 vector (Renilla luciferase, Promega), which was cotransfected as an internal control. A 10 ml of cell lysate was assayed for luciferase activity using a luminometer (Lumat LB9501, EG & G Berthold, Bad Wildbad, Germany) . The values were means of three independent experiments. Statistical analyses were made by Kruskal-Wallis test and Scheffe's test. A tied P-value with less than 0.05 was considered as significant.
Gel mobility shift assay and competition study
Nuclear extracts from E2-treated and untreated cultured endometrial glandular cells were prepared by the modified Dignam method. The gel shift assay was performed as described previously (Kawasaki et al., 1999) . In brief, three 20 base single-stranded DNA oligomers termed PRAD-D1, corresponding to regions À958 to À940 (5 0 -AAAAATGAGT-CAGAATGGAG-3 0 ), which included the AP-1 sequence at À953 to À947, PRAD-M (5 0 -AAAAACAAGTTGGAATG-GAG-3 0 ), which contained four introduced mutation sites on the AP-1 sequence (TGAGTCA-CAAGTTG) and PRAD-C (5 0 -AAAAATGACTCAGAATGGAG-3 0 ), which included a consensus AP-1-binding domain (TGACTCA), were synthesized, annealed and end-labeled with [ 32 P]dCTP using the Klenow enzyme. For the competition studies, a 10-50-fold molar excess of the three unlabeled DNA oligomers above was used (PRAD-D1; 10-fold, PRAD-M; 50-fold, PRAD-C; 10-fold). For the supershift assay, 0.5 mg of antibody against for c-Jun or c-Fos (Santa Cruz Biotechnology in Figure 5a , Oncogene in Figure 5b ) was incubated for 15 min at room temperature after the binding reaction. The bands were analysed with the MacBAS system (Fuji Film, Tokyo, Japan) 
